The core(established)cerebrospinal fluid biomarkers of Alzheimer's disease(AD),namely amyloid-beta peptide,total tau protein and phospho-tau protein,have become a part of the diagnostic workup of patients with cog...The core(established)cerebrospinal fluid biomarkers of Alzheimer's disease(AD),namely amyloid-beta peptide,total tau protein and phospho-tau protein,have become a part of the diagnostic workup of patients with cognitive disorders in many specialized centers,especially for ambiguous cases.Combined,these biomarkers can identify the presence or absence of an AD biochemical process with sensitivities and specificities approaching or exceeding 90%in both dementia and pre-dementia stages of AD.Thus,they have been incorporated in various sets of research or clinical diagnostic criteria and recommendations.Results that are atypical,incompatible with AD,or inconclusive may occur,necessitating the use of other cerebrospinal fluid or imaging biomarkers.展开更多
The classical cerebrospinal fluid biomarkers of Alzheimer's Disease (namely total tau, phospho-tau and amyloid beta peptide) have received much attention, since they can detect the biochemical fingerprint of Alzhe...The classical cerebrospinal fluid biomarkers of Alzheimer's Disease (namely total tau, phospho-tau and amyloid beta peptide) have received much attention, since they can detect the biochemical fingerprint of Alzheimer's disease and serve as a diagnostic aid for correct diagnosis of cognitive disorders during life. In this case series, we present 6 examples of patients with cognitive impairment of various types and severities and how biomarker data were helpful in every day diagnostic approach, combined with clinical, neuropsychological and imaging data and based on the most recent guidelines and recommendations.展开更多
文摘The core(established)cerebrospinal fluid biomarkers of Alzheimer's disease(AD),namely amyloid-beta peptide,total tau protein and phospho-tau protein,have become a part of the diagnostic workup of patients with cognitive disorders in many specialized centers,especially for ambiguous cases.Combined,these biomarkers can identify the presence or absence of an AD biochemical process with sensitivities and specificities approaching or exceeding 90%in both dementia and pre-dementia stages of AD.Thus,they have been incorporated in various sets of research or clinical diagnostic criteria and recommendations.Results that are atypical,incompatible with AD,or inconclusive may occur,necessitating the use of other cerebrospinal fluid or imaging biomarkers.
文摘The classical cerebrospinal fluid biomarkers of Alzheimer's Disease (namely total tau, phospho-tau and amyloid beta peptide) have received much attention, since they can detect the biochemical fingerprint of Alzheimer's disease and serve as a diagnostic aid for correct diagnosis of cognitive disorders during life. In this case series, we present 6 examples of patients with cognitive impairment of various types and severities and how biomarker data were helpful in every day diagnostic approach, combined with clinical, neuropsychological and imaging data and based on the most recent guidelines and recommendations.
